Till now, pharma companies, opposing price control, have been trying to make their voices heard in the corridors of power. With the courts recently stepping in to bring essential medicines under a price control regime, multinational-led industry body OPPI (Organization of Pharmaceutical Producers of India) has moved the Supreme Court seeking to be heard on the drug pricing issue.
OPPI through an application seeking "impleadment" in the ongoing public interest litigation on the drug pricing issue in the Supreme Court, wants to be a formal party in the case. Sources said that the OPPI filed the application to engage with the government "more actively'', and wanted to ensure that its case is heard.
The PIL was filed by health groups led by All India Drug Action Network, seeking essential drugs to be regulated under a price control regime in 2003. The "impleadment" application was filed on November 12, and later admitted by the court. "The OPPI moved the Supreme Court to get impleaded as a party in the ongoing PIL because the drug pricing issue affects our industry's ability to sustainably provide medicines-both innovative and generic-to the population in India, and, hence will have an effect on public health and access to medicines, as well as the economic development of the pharma industry," OPPI president Ranjit Shahani told TOI.
OPPI through an application seeking "impleadment" in the ongoing public interest litigation on the drug pricing issue in the Supreme Court, wants to be a formal party in the case. Sources said that the OPPI filed the application to engage with the government "more actively'', and wanted to ensure that its case is heard.
The PIL was filed by health groups led by All India Drug Action Network, seeking essential drugs to be regulated under a price control regime in 2003. The "impleadment" application was filed on November 12, and later admitted by the court. "The OPPI moved the Supreme Court to get impleaded as a party in the ongoing PIL because the drug pricing issue affects our industry's ability to sustainably provide medicines-both innovative and generic-to the population in India, and, hence will have an effect on public health and access to medicines, as well as the economic development of the pharma industry," OPPI president Ranjit Shahani told TOI.
No comments:
Post a Comment